Compare · LIVN vs ZYXI
LIVN vs ZYXI
Side-by-side comparison of LivaNova PLC (LIVN) and Zynex Inc. (ZYXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and ZYXI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $3.51B, about 11.8x ZYXI ($296.3M).
- Over the past year, LIVN is up 71.1% and ZYXI is down 94.1% - LIVN leads by 165.2 points.
- LIVN has hit the wire 1 time in the past 4 weeks while ZYXI has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 10 for ZYXI).
- Company
- LivaNova PLC
- Zynex Inc.
- Price
- $64.18-1.47%
- $0.13-31.48%
- Market cap
- $3.51B
- $296.3M
- 1M return
- +1.42%
- -77.93%
- 1Y return
- +71.15%
- -94.10%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 1
- 0
- Recent ratings
- 20
- 10
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Zynex Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Latest LIVN
- Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
- SEC Form 4 filed by Tezel Ahmet
- SEC Form 4 filed by Poletti Franco
- SEC Form 4 filed by Makatsaria Vladimir
- SEC Form 4 filed by Shvartsburg Alex
- SEC Form 4 filed by Bolton Stephanie
- SEC Form 4 filed by Kozmina Natalia
- MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
- LivaNova to Announce First-Quarter 2026 Results
- LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
Latest ZYXI
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Zynex Financial Restructuring Puts Company on Path to Long-Term Success
- SEC Form 3 filed by new insider Aronzon Paul
- SEC Form 10-Q filed by Zynex Inc.
- Zynex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zynex Reports Third Quarter 2025 Financial Results
- Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee
- Zynex Sets Third Quarter 2025 Earnings Call
- SEC Form NT 10-Q filed by Zynex Inc.